the Nominating and Governance Committee, in consultation with the Chairman of the Board, reviews each director’s continuation on the Board as a regular part of the annual nominating process. Under the advance notice provisions of our By‐Laws, director nominations and proposals by our stockholders to bring any other business before the

Chief Executive Officer Succession Pursuant to our Corporate Governance Guidelines, the Nominating and Governance Committee reports to the full Board periodically on succession planning for our Chief Executive Officer (and other executive officers, as appropriate). Our Chief Executive Officer discusses with the Board and the Nominating and Governance Committee, at least once per year, his recommendations and evaluations of potential successors to his position, including in the event of an unexpected emergency, and reviews development plans, if any, recommended for such individuals who are current employees of the Company. Additionally, the Nominating and Governance Committee conducts an annual review of the CEO Succession Plan framework, which outlines certain high‐level planning, notification and other actions, and is designed to minimize disruption in the event of a temporary or permanent absence of the Chief Executive Officer. Board Leadership Structure Our Board believes that it is important that it retain flexibility to make the determination as to whether the interests of the Company and our stockholders are best served by having the same individual serve as both Chief Executive Officer and Chairman of the Board, or whether the roles should be separated based on the circumstances at any given time. Under our Corporate Governance Guidelines, the Board will appoint a Lead Independent Director when the Chief Executive Officer and Chairman of the Board roles are combined, or if the Chairman is not otherwise independent. Pursuant to our Corporate Governance Guidelines, the Lead Independent Director is appointed annually, though is generally expected to serve for a renewable term of three years, subject to the Lead Independent Director’s annual re‐election to the Board. The Lead Independent Director will preside over meetings of our non‐management directors, serve as liaison between our Chairman and the independent directors, work with the Chairman to establish agendas for Board and committee meetings, raise issues with management on behalf of the independent directors, consult with committee leadership, and carry out other duties as requested by the Board. The Lead Independent Director also has the authority to call special meetings of independent or non‐management directors, as needed. Mr. Mahoney has been our President and Chief Executive Officer since November 2012 and the Chairman of our Board since May 2016. In light of the fact that the Chief Executive Officer and Chairman of the Board roles have been combined since May 2016, the Board appointed Mr. Ludwig at that time to serve as Lead Independent Director and re‐appointed him to serve in that role for additional three‐year terms in February 2019 and February 2022. Mr. Ludwig’s qualifications to serve as our Lead Independent Director include his strong leadership experience as the former Chief Executive Officer and Chairman of the Board of Becton, Dickinson and Company, his current service on the Board of CVS Health Corporation and the Chair of that board’s Audit Committee, and as lead director on the Board of Aetna, Inc. prior to its acquisition by CVS Health Corporation. Our Board believes that this leadership structure, coupled with a commitment to Board independence, provides effective, independent oversight of management, while fostering a constructive and cooperative relationship between the Board and management and allowing both the Board and management to benefit from Mr. Mahoney’s day‐to‐day familiarity with our business operations. Board Evaluations Our Board of Directors conducts annual self‐evaluations, overseen by the Nominating and Governance Committee in accordance with the committee’s charter. The committee has engaged a third‐party consultant to facilitate the self‐evaluations through a mix of in‐person and telephonic interviews. At the conclusion of the process, the facilitator provides written reports to the Board and reviews results with Board leadership. 28 Toppan Merrill - Boston Scientific DEF 14A Typeset ED | 111250 | 15-Mar-22 08:21 | 22-3423-2.ea | Sequence: 4 CHKSUM Content: 46913 Layout: 38269 Graphics: 0 CLEAN JOB: 22-3423-2 CYCLE#;BL#: 4; 0 TRIM: 8.25" x 10.75" AS: Daniels Boston: 617-443-9700 COLORS: Black, ~note-color 2 GRAPHICS: none V1.5

Given the Board’s role in risk oversight, it believes that any leadership structure that it adopts must allow it to effectively oversee the management of the risks relating to our operations. Although there are different leadership structures that could allow our Board to oversee risk management effectively, and while our Board believes our current leadership structure will enable it to manage such risks effectively, it was one factor among many considered by our Board in selecting this leadership structure over other potential alternatives. For a discussion of the reasons why our Board has determined that its leadership structure is appropriate, please see the “Board Leadership Structure” above. Communications with the Board Stockholders and other interested parties who wish to communicate directly with any member of our Board, the Board as a group, or our non‐management directors as a group, may do so by writing to the Board of Directors or Non‐Management Directors, Boston Scientific Corporation, c/o General Counsel, 300 Boston Scientific Way, Marlborough, Massachusetts 01752 or by contacting the Board via email at BSCboardofdirectors@bsci.com or non‐management directors at non‐managementdirectors@bsci.com. The Board has authorized the office of our General Counsel to review and organize, but not screen, communications from stockholders and other interested parties and deliver them to the Board or non‐management directors, as applicable. We do screen commercial solicitations for appropriateness. The Company is committed to stockholder engagement. In addition to the communication process detailed above, stockholders also have the opportunity to speak at our Annual Meeting of Stockholders, participate in the annual “say‐on‐pay” advisory vote and communicate with our active Investor Relations department, among other avenues for engagement. The Board seriously considers the views of stockholders in its decision‐making process. For example, based on engagement with our stockholders and benchmarking of corporate governance best practices, the Board determined that it was in the best interest of the Company and our stockholders to: • amend the Company’s Corporate Governance Guidelines to require that women and racially/ethnically diverse candidates be included among the initial slate of candidates presented for consideration in external searches for a Chief Executive Officer and new Board members; • approve amendments to the By‐Laws to allow for proxy access, a process by which stockholders meeting certain requirements can nominate directors for election using the Company’s proxy materials; and • recommend that stockholders approve amendments to the Company’s By‐Laws implementing a majority voting standard in uncontested director elections. The Board values the input of the stockholders who engaged with us on these important matters, and believes that the changes enhance stockholder rights, provide increased accountability of the Company and our Board to our stockholders, and give us an opportunity to further demonstrate our values and commitment to advancing diversity, equity and inclusion. Board and Committee Service Limitation Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including our Board) and our Chief Executive Officer may not sit on more than two public company boards (including our Board). No director may serve simultaneously on the audit committees of more than three public companies (including the Company), unless the Board of Directors has determined that such service would not impair the ability of the member to effectively serve on the Company’s Audit Committee, such determination to be disclosed in accordance with applicable NYSE and SEC rules. All of our Board members have 30 Toppan Merrill - Boston Scientific DEF 14A Typeset ED | 111250 | 15-Mar-22 08:21 | 22-3423-2.ea | Sequence: 6 CHKSUM Content: 56164 Layout: 40890 Graphics: 0 CLEAN JOB: 22-3423-2 CYCLE#;BL#: 4; 0 TRIM: 8.25" x 10.75" AS: Daniels Boston: 617-443-9700 COLORS: Black, ~note-color 2 GRAPHICS: none V1.5

Each

Each non‐employee director receives the annual cash retainer and fees on a quarterly basis. For 2021, each non‐ employee director could elect to receive all or a portion of his or her cash compensation as one or both of two equity alternatives, each to vest on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director’s continuation of service during such term: (i) restricted stock valued based on the closing price of our common stock on the date of grant; and (ii) deferred stock units, valued based on the closing price of our common stock on the date of grant (with shares of our common stock to be issued only after a director’s separation from Board service in accordance with the Boston Scientific Non‐Employee Director Deferred Compensation Plan, as amended and restated, effective January 1, 2014 (the 2014 Non‐Employee Director Deferred Compensation Plan)). Each non‐employee director could also choose to defer receipt of all or a portion of his or her annual cash compensation under the 2014 Non‐Employee Director Deferred Compensation Plan, as described further below. The annual equity grants are made on the date of each annual meeting of stockholders and are subject to the terms and conditions of our Amended and Restated 2011 Long‐Term Incentive Plan (2011 LTIP). In 2021, each non‐employee director could elect to receive his or her annual equity award as one or both of the following two equity compensation alternatives, each to vest on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director’s continuation of service during such term: (i) restricted stock valued based on the closing price of our common stock on the date of grant; and (ii) deferred stock units valued based on the closing price of our common stock on the date of grant (with shares of our common stock to be issued only after a director’s separation from Board service in accordance with the 2014 Non‐Employee Director Deferred Compensation Plan). At the 2020 Annual Meeting of Stockholders, our stockholders voted to approve an amendment and restatement of the 2011 LTIP, which, among other changes, provided that a reasonable annual limit would be imposed on the cash and equity compensation that may be granted or paid to any non‐employee director during a calendar year so that the accounting value of equity awards, when aggregated with cash compensation, granted to a non‐ employee director in any calendar year does not exceed $600,000. Employee Directors Directors who are also employees of the Company receive no compensation for serving on the Board or committees. Other Payments and Benefits We pay for, or reimburse our directors for, transportation, hotel, meals and other incidental expenses incurred in connection with their performance of services for us, including attending Board and committee meetings and participating in director education programs. Our corporate aircraft is made available to our directors for travel to and from our Board meetings, as well as for certain other Company business travel. We also extend directors’ and officers’ indemnity insurance coverage to each of our directors. Cash Compensation Equity Compensation Amendment and Restatement of 2011 LTIP 40 Toppan Merrill - Boston Scientific DEF 14A Typeset ED | 111250 | 15-Mar-22 08:21 | 22-3423-2.fa | Sequence: 8 CHKSUM Content: 21411 Layout: 2446 Graphics: 12273 CLEAN JOB: 22-3423-2 CYCLE#;BL#: 4; 0 TRIM: 8.25" x 10.75" AS: Daniels Boston: 617-443-9700 COLORS: Yellow, C100 M84 Y30 K16, Cyan, ~note-color 2, Black, Magenta GRAPHICS: 3423-2_Direct_Icon.eps, 3423-2_Direct_Icon.eps, 3423-2_Direct_Icon.eps V1.5

Compensation. For a description of the assumptions used for purposes of determining grant date fair value, please see NoteL—Stock Ownership Plans to our consolidated financial statements included in Item 8 — Financial Statements and Supplementary Data of our Annual Report on Form 10‐K for the year ended December 31, 2021. (3) Ms. Connors elected to receive 50% of her cash retainer earned in 2021 as equity in the form of restricted stock. Mr. Dockendorff elected to receive 75% of his cash retainer and fees earned in 2021 as equity in the form of restricted stock. Mr. Wichmann elected to receive all of his cash retainer earned in 2021 as equity in the form of deferred stock units. The following table reports the equity granted to Ms. Connors, Mr. Dockendorff and Mr. Wichmann in lieu of cash for the one‐year term beginning after the 2021 Annual Meeting of Stockholders, and, in the case of Mr. Wichmann, for the portion of such term following the date of his appointment to the Board. Number of Grant Date Name Equity Award Grant Date Units(#) Fair Value($) Vesting Date Nelda J. Connors Restricted Stock May 6, 2021 1,335 57,500 May 5, 2022 Charles J. Dockendorff Restricted Stock May 6, 2021 2,439 105,100 May 5, 2022 David S. Wichmann Deferred Stock Units July 1, 2021 2,296 99,600 May 5, 2022 (4) Each non‐employee director elected at our 2021 Annual Meeting of Stockholders was granted an equity award with a value of $205,000. For each director that elected to receive restricted stock, the restricted stock vests on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director’s continued service during such term. For each director that elected to receive deferred stock units, the deferred stock units vest on the date of the annual meeting of stockholders immediately following the date of grant, subject to continued service during such term, and vested shares of stock will be issued to the director upon his or her separation from Board service in accordance with the 2014 Non‐Employee Director Deferred Compensation Plan. The award to Mr. Wichmann represents the annual equity award for the 2021 term prorated for the period from the effective date of his appointment to the date of the 2022 Annual Meeting of Stockholders. The annual equity awards to our directors during 2021 are shown below: Number of Shares/ Grant Date Name Equity Award Grant Date Units(#) Fair Value($) Vesting Date Nelda J. Connors Restricted Stock May 6, 2021 4,763 205,000 May 5, 2022 Charles J. Dockendorff Restricted Stock May 6, 2021 4,763 205,000 May 5, 2022 Yoshiaki Fujimori Deferred Stock Units May 6, 2021 4,763 205,000 May 5, 2022 Donna A. James Deferred Stock Units May 6, 2021 4,763 205,000 May 5, 2022 Edward J. Ludwig Deferred Stock Units May 6, 2021 4,763 205,000 May 5, 2022 David J. Roux Restricted Stock May 6, 2021 4,763 205,000 May 5, 2022 John E. Sununu Restricted Stock May 6, 2021 4,763 205,000 May 5, 2022 David S. Wichmann Deferred Stock Units July 1, 2021 4,093 177,489 May 5, 2022 Ellen M. Zane Restricted Stock May 6, 2021 4,763 205,000 May 5, 2022 The outstanding Restricted Stock, Restricted Stock Deferred and Deferred Stock Units held by the non‐employee directors at December 31, 2021 are shown below: Outstanding Deferred Outstanding Stock Units and Restricted Name Restricted Stock Stock Deferred Nelda J. Connors 6,098 77,569 Charles J. Dockendorff 7,202 — Yoshiaki Fujimori — 27,874 Donna A. James — 23,247 Edward J. Ludwig — 37,436 David J. Roux 4,763 — John E. Sununu 4,763 81,757 David S. Wichmann — 6,389 Ellen M. Zane 4,763 — For more information on the beneficial ownership of our directors, please see the section titled “Certain Beneficial Ownership Matters”. 42 Toppan Merrill - Boston Scientific DEF 14A Typeset ED | 111250 | 15-Mar-22 08:21 | 22-3423-2.fa | Sequence: 10 CHKSUM Content: 24398 Layout: 60585 Graphics: 0 CLEAN JOB: 22-3423-2 CYCLE#;BL#: 4; 0 TRIM: 8.25" x 10.75" AS: Daniels Boston: 617-443-9700 COLORS: C100 M84 Y30 K16, ~note-color 2, Black GRAPHICS: none V1.5

Our Executive Officers As of March 11, 2022, our executive officers were: Name Age Title Michael F. Mahoney 57 Chairman of the Board, President and Chief Executive Officer

Professor Ian T. Meredith AM